Anupam Rasayan, a prominent player in custom synthesis and specialty chemicals in India, has recently signed a Letter of Intent (LOI) with a leading Japanese specialty chemical company. The agreement entails a projected revenue of $265 million (Rs 21.86 billion) over the course of the next five years. The purpose of this partnership is to supply a new-age patented life science active ingredient.
The product in question is currently in the validation phase, which is expected to last for the next eighteen months. During this period, rigorous testing and evaluation will be conducted to ensure the product meets the necessary standards and specifications. Upon successful validation, the supply of the product will commence in the calendar year 2025.
To facilitate the manufacturing process, Anupam Rasayan will utilize its existing multi-purpose manufacturing facilities. These facilities are well-equipped to handle the production of the new-age patented life science active ingredient. By utilizing its current infrastructure, Anupam Rasayan aims to streamline the manufacturing process and ensure efficient production of the product.
Speaking about the contract, Anand Desai, Managing Director of Anupam Rasayan, said, “We are pleased to announce that we will be the primary global supplier of this new age patented life science active ingredient to one of the leading Japanese specialty chemical companies with the support of our Japanese business development team. With the addition of this new customer, we are delighted to include another renowned Japanese multinational in our customer portfolio. As we are fully backward integrated for this molecule, we can provide supply chain assurance to the customer without dependencies on supplies from other geographies.”
“The signing of this LOI represents a significant milestone for us, further cementing our position as a trusted provider of high-end customized molecules. We are excited about the opportunities this partnership brings.”